Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger
Amgen said Monday that it will buy the psoriasis pill Otezla from Celgene, which is selling the medicine to remove an antitrust obstacle from its planned merger with Bristol-Myers Squibb.
The purchase price for Otezla is $13.4 billion — higher than many analysts expected.
